Rare Genetic Epilepsy Responsive To Marinus's Ganaxolone
Meets Primary Endpoint In Phase III MARIGOLD Study
Marinus Pharmaceuticals has transformed its finances and the prospects for its R&D pipeline over the past 12 months, and has just reported positive top-line results from the Phase III MARIGOLD study of its lead compound, ganaxolone.
You may also be interested in...
After multiple failed attempts to treat rare conditions, Marinus is on the cusp of success with ganaxolone in genetic epilepsy, and has secured a new European partner in Orion.
US incentive program would gain only four more years, despite calls for a permanent extension.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.